JCI:预测丙型肝炎病毒复发的标志物

2014-07-04 佚名 不详

在世界各地,百万计人感染了丙型肝炎病毒(HCV),HCV可导致肝硬化和肝癌症。直接作用的抗病毒剂能抑制病毒蛋白,并已成功地用于治疗HCV。 不幸的是,抗病毒治疗在一些患者中失败,导致丙型肝炎病毒复发。 发表在Journal of Clinical Investigation杂志的一项研究确定了一种标记,它可以识别患者在抗病毒治疗后是否可能有HCV复发。主要研究人员Shyamasundara

在世界各地,百万计人感染了丙型肝炎病毒(HCV),HCV可导致肝硬化和肝癌症。直接作用的抗病毒剂能抑制病毒蛋白,并已成功地用于治疗HCV。

不幸的是,抗病毒治疗在一些患者中失败,导致丙型肝炎病毒复发。

发表在Journal of Clinical Investigation杂志的一项研究确定了一种标记,它可以识别患者在抗病毒治疗后是否可能有HCV复发。主要研究人员Shyamasundaran Kottilil和美国国家卫生研究院的同事评价抗病毒药物治疗丙型肝炎病毒感染者的免疫反应。

结果发现那些I型干扰素表达增加的治疗患者更有可能免于复发。无法维持I型干扰素的患者更可能有HCV复发。这项研究提供了一个潜在的标记,以确定患者是否易发生HCV复发。

原始出处

Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S.Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.J Clin Invest. 2014 Jul 1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840812, encodeId=7b851840812c8, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 19 12:09:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981983, encodeId=6d42198198322, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Jun 03 16:09:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274555, encodeId=043d12e455550, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429528, encodeId=d1d214295287f, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840812, encodeId=7b851840812c8, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 19 12:09:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981983, encodeId=6d42198198322, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Jun 03 16:09:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274555, encodeId=043d12e455550, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429528, encodeId=d1d214295287f, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840812, encodeId=7b851840812c8, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 19 12:09:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981983, encodeId=6d42198198322, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Jun 03 16:09:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274555, encodeId=043d12e455550, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429528, encodeId=d1d214295287f, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840812, encodeId=7b851840812c8, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Sep 19 12:09:00 CST 2014, time=2014-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981983, encodeId=6d42198198322, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Jun 03 16:09:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274555, encodeId=043d12e455550, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429528, encodeId=d1d214295287f, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Sun Jul 06 00:09:00 CST 2014, time=2014-07-06, status=1, ipAttribution=)]

相关资讯

WHO发布丙型肝炎指南

  4月10日,世界卫生组织(WHO)于2014 EASL年会上发布《丙型肝炎筛查、关怀和治疗指南》。该指南在国际新型小分子抗病毒药物风起云涌的今年,特别考虑到资源有限地区的经济和社会发展情况。其相对于其他丙型肝炎指南的特点是,不仅仅考虑到治疗的有效性,还考虑到筛查和患者关怀。该指南有9个策略性建议,分别如下:   筛查   建议对所有丙型肝炎病毒(HCV)高感染率

NEJM:中低收入国家丙型肝炎治疗面临的挑战

丙型肝炎病毒(HCV)被识别后仅仅20年,对病毒生命周期认识的不断提高产生了一些新型的极具潜力的治疗方法。最早到2015年,大多数HCV基因型患者的持续病毒学应答率将达90%左右。短期,无干扰素,固定剂量,单药治疗的便捷方案可有效“治愈”HCV,且不良反应明显优于既往疗法。 使用这些药物有望降低随访监测频次,因不良反应住院治疗的比率,对专家治疗的依赖程度以及疾病进展相关资源需求,包括肝移植以及

BMJ:2030年可能基本消除丙型肝炎

肝脏病学领域的专家预测认为,在未来的几十年之内,如果新的抗HCV药物如早期研究所显示出的有效性,且相关的措施可诊断出更多能够接受治疗的患者,丙型肝炎可能不再被认为是一个严重的公共卫生问题。 第49届欧洲肝病研究学会年会暨2014年国际肝病会议召开前夕,在由丙肝基金会举办的新闻发布会上,伦敦帝国学院肝脏病学教授Mark Thursz认为丙型肝炎治疗环境在过去几年中已经发生了彻底的改变。 丙肝基金

病例报告:干扰素致甲状腺功能异常1例

  病例资料   患者男性,37岁,汉族,北京籍,教师。因“发现ALT升高5年,间断心悸1年余”就诊。患者5年前劳累后感觉乏力,检查结果显示:ALT 67U/L、抗-HCV阳性。1年半前HCV RNA水平为2.8×105拷贝/ml,并开始干扰素α-2b 3MU/d治疗,未服用利巴韦林;治疗3个月时查HCV RNA低于检测限。但患者在治疗

BMS在日本提交丙型肝炎全口服治疗药物的上市申请

美国制药商百时美施贵宝于11月3日表示,该公司已向日本卫生监管机构提交了其全口服丙型肝炎试验药物的上市申请。这次向日本药品和医疗器械局提交上市申请标志着制药商第一次提交不包含两种标准老药的丙型肝炎治疗药物的上市申请,老药包括干扰素注射剂或利巴韦林药丸。吉利德科学公司被普遍认为是开发高效、无干扰素的严重肝病治疗药物方面的领先者,该公司已向美国提出了备受关注的由Sofosbuvir和利巴韦林组成的抗病

百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%

根据4月10发布的一项后期临床研究结果,由百时美施贵宝研发的两种抗病毒药物组成的复方药物,对之前未经治疗的丙型肝炎患者的治愈率达到了90%,对之前治疗无效患者的治愈率达到82%。 3期临床试验Hallmark-Dual有700多名受试者参与,该试验在基因型1b受试者中对百时美施贵宝Daclatasvir和Asunaprevir的复方药物进行了检测,试验周期超过24周,基因型1b病毒可导致渐进性的肝